Interferon Gamma-1b
- Atc Codes:L03AB03
- CAS Codes:98059-61-1
- PHARMGKB ID:98059-61-1
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Toxicological Effects
- Genes that may be involved
- Inhibits
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Imukin; Belgium: Immukine; Cyprus: Imukin; Czech Republic: Imukin; Denmark: Imukin; Finland: Imukin; France: Imukin; Germany: Imukin; Greece: Imukin; Ireland: Immukin; Italy: Imukin; Luxembourg: Immukin; Malta: Immukin; Netherlands: Immukine; Portugal: Imukin; Spain: Imukin; Sweden: Imukin; UK: Immukin.
North America
USA: Actimmune.
Latin America
Argentina: Imukin.
Drug combinations
Chemistry
Interferon Gamma-1b: C~734~H~1166~N~204~O~216~S~5~. Mw: 16464.69. (1) 1-139-Interferon γ (human lymphocyte protein moiety reduced), N2-L-methionyl-; (2) N^2^-L-Methionyl-1-139-interferon γ (human lymphocyte protein moiety reduced). CAS-98059-61-1 (1987).
Pharmacologic Category
Biologic Response Modifiers. (ATC-Code: L03AB03).
Mechanism of action
Interferon gamma participates in immunoregulation by enhancing oxidative metabolism of macrophages. Also enhances antibody-dependent cellular cytotoxicity, activates natural killer cells and has a role in expression of Fc receptors and histocompatibility antigens. Exact mechanism of action for treatment of chronic granulomatous disease or osteopetrosis not defined.
Therapeutic use
Reduction of frequency and severity of serious infections associated with chronic granulomatous disease. Delay of time to disease progression in severe, malignant osteopetrosis.
Pregnancy and lactiation implications
Teratogenic effects not observed in animal studies. Abortifacient activity reported in Rhesus monkeys. Safety and efficacy in pregnant women not established. Not recommended during lactation.
Unlabeled use
Contraindications
Hypersensitivity to interferon gamma, E. coli-derived proteins, or any component of the formulation.
Warnings and precautions
Dose-related bone marrow toxicity reported (use caution in myelosuppression). Development of neurologic disorders (use with caution in history of seizure disorder or compromised CNS function). Flu-like symptoms (at higher doses) may exacerbate pre-existing cardiovascular disorders (including ischemia, heart failure, or arrhythmias). May cause hepatotoxicity (increased incidence in children <1 year of age). Hypersensitivity reactions reported (rarely). Transient cutaneous rashes may occur. Use with caution in cardiovascular disease.